Official UK procurement notice
Gonadorelin Analogues · UK public procurement notice
Authority: The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) (NHS & healthcare)
What is being bought2 lots · detail below
Published requirement descriptionSupply of Gonadorelin Analogues to NHS Scotland.
CPV: Pharmaceutical products
How this framework works
From the published notice- Bids received
- 1 bids on the busiest of 2 lots · 2 suppliers appointed
Lots and requirements (2)Procurement structure
2 lots · no lot values publishedLot #1NP90219b Leuprorelin (Prostap®)Awarded
The supply of Leuprorelin (Prostap®) to NHS Scotland. The Authority has awarded this Lot as a single supplier framework agreement to one (1) Framework Participant.
Lot #2NP90219c Triptorelin (Decapeptyl®)Awarded
The supply of Triptorelin (Decapeptyl®) to NHS Scotland. The Authority has awarded this Lot as a single supplier framework agreement to one (1) Framework Participant.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Award procedure without prior publication of a call for competition
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 9 Nov 2023, 10:59 GMT
- Last source update
- 17 Jan 2024, 14:22 GMT
- Authority reference
NP90219- FTS notice number
2024/S 000-001623- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-041700Find a Tender
- Why no open competition
- The procurement falls outside the scope of application of the directive
- Published justification
This VEAT Notice is to advise the need for modification to meet the additional demands of the Scottish Health and Social Care sector during the Covid-19 pandemic and associated recovery, to maintain supply and remove unnecessary disruption from the Authority at this time in line with Regulation 72(1)(b) of the Public Contracts (Scotland) Regulations 2015.
- Review procedure
The notification will incorporate a ‘standstill period’ of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority despatches the VEAT notice and the date on which the Authority proposes to conclude the relevant framework agreement.
The bringing of court proceedings against the authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer.
The bringing of court proceedings against the authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.
Publisher note: The estimated value(s) of the Framework Agreement referred to in Section V.2.4 comprising two (2) lots cover the twelve (12) month duration of the proposed modification period of the Framework Agreement. (SC Ref:755510)
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast4 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.
Contracts
All 2 of these contracts carry the same published figure, £423,304, the framework's maximum for the whole notice, not each contract's own value. They are not eleven separate sums.
NP90219b Leuprorelin (Prostap®)
- Signed
- 9 Nov 2023
- Value
- ceiling above
- Status
- active
NP90219c Triptorelin (Decapeptyl®)
- Signed
- 9 Nov 2023
- Value
- £405,778
- Status
- active
NP90219b Leuprorelin (Prostap®)
- Signed
- 9 Nov 2023
- Value
- ceiling above
- Status
- active
NP90219c Triptorelin (Decapeptyl®)
- Signed
- 9 Nov 2023
- Value
- £405,778
- Status
- active
Bid statistics published by the authority
| Lot | Bids | SME | VCSE | Valid bid range |
|---|---|---|---|---|
| 1 · NP90219b Leuprorelin (Prostap®) | 1bids · 1 electronic | 0 | — | — |
| 2 · NP90219c Triptorelin (Decapeptyl®) | 1bids · 1 electronic | 0 | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- Sheriff Court HouseReview body
Framework contractors & participating bidders
2 commercial parties on the notice- Ipsen LtdFramework contractor
- Takeda UK LimitedFramework contractor
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.